The Webinar Series will take place bi-weekly on: Thursdays

12 pm noon (EST)

9 am (PST), 5 pm (GMT), 6 pm (CET)

Registration is required for each seminar.

You can join the webinar by Zoom.

Some seminars might be recorded and accessible for a limited time.

Upcoming Speakers

December 3rd, 2020 

Small-molecule-induced protein polymerization

Webinar registration:

https://dfci.zoom.us/webinar/register/WN_rOAQV4c8Tge2bXW23l9rYQ

Host: Katherine Donovan

 
 
 

Researchers from the Ebert and Fischer lab teamed up to solve the elusive mechanism of a BCL6 degrader, BI-3802. By employing functional screens, biochemical dissection, and structural characterization, they identified that BI-3802 induces BCL6 polymerization, which triggers proteasomal degradation of BCL6. The seminar will be presented by Mikolaj Slabicki (Ebert Lab), Hojong Yoon (Fischer Lab), and Jonas Koeppel (Ebert Lab).

December 17th, 2020 

What makes two proteins stick: dissecting molecular glue action

 

Webinar registration:

https://dfci.zoom.us/webinar/register/WN_Hr3R9LRoRUagwczvrWsO7g

Host: Mikolaj Slabicki

 
 
 
 

The Thomä laboratory is interested in chromatin-bound machines and their regulation by the ubiquitin proteasome system. Guided by structural biology, we use a range of genetic, chemical and complex biochemical reconstitution tools to study protein function in genome maintenance and transcription. A particular focus is on dissecting how chromatin and the ubiquitin transferase system interplay. In recent years, the lab worked towards understanding how proteins, such as ubiquitin ligases, can be re-programmed by small molecules, and how this insight can be used to develop novel drugs.

Dr Nicolas Thomä is a group leader at the Friedrich Miescher Institute in Basel, Switzerland. He is an elected member of the European Molecular Biology Organization (EMBO) and of Academia Europeana. Dr Thomä is the recipient of the Novartis Leading Scientist Award and holds an ERC Advanced Grant.

January 21st, 2021 

TBA

Host: Alyssa Verano

 

Brenda Schulman is a Director at the Max Planck Institute of Biochemistry.  She is broadly interested in how ubiquitin and ubiquitin-like proteins are matched with specific substrates, and how they alter the functions of their targets to regulate the cell cycle, autophagy, metabolic signaling, differentiation and other biological processes.  Her lab structurally visualizes transient ubiquitylation complexes trapped as if in action, biochemically reconstitutes signaling pathways, develops chemical tools to probe ubiquitin signaling, and employs cell biology to investigate how ubiquitylation mediates regulation.  Schulman is an elected member of American Academy of Arts and Sciences, the National Academy of Sciences, EMBO, and the German National Academy Leopoldina, and has been recognized by awards including most recently the Gottfried Wilhelm Leibniz Prize and Ernst Jung Prize for Medicine.

February 2nd, 2021 

TBA

Host: Radek Nowak

 

James (Jay) Bradner

James (Jay) Bradner, M.D., joined Novartis on January 1, 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) on March 1, 2016. He is a member of the Executive Committee of Novartis.
Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. Dr. Bradner is a co-founder of five biotechnology companies and has authored more than 250 scientific publications and 50 US patent applications.
Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women's Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.